By: Ana Elcarte

Columbus VP leads the new investment round of Integra Therapeutics with €1.5M

The biotechnology firm completes the seed round funding with a total of €6 million led last December by AdBio Partners, Invivo... Read More
Artax Biopharma Announces First-in-Human Dosing for AX-158

First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company's First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases The Phase 1... Read More
Aleta Biotherapeutics Announces ALETA-001

Aleta Biotherapeutics Announces ALETA-001 Poster Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting Pre-clinical results demonstrate durable response... Read More
Vifor Pharma to acquire Sanifit

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical... Read More
Highlight Therapeutics: Positive Phase 2b results in 2nd line melanoma

Highlight Therapeutics presents a medical breakthrough at the SITC oncology congress, being the first time that a drug shows a positive... Read More
Aura Biosciences is trading on the Nasdaq Global Market

Columbus Venture Partners Portfolio Company, Aura Biosciences, is trading on the Nasdaq Global Market Aura Biosciences (Cambridge, USA), whose founder is... Read More
Arcline Investment Management Acquires PTS

VALENCIA, Spain, April 27, 2021 -- Arcline Investment Management ("Arcline"), a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, today announced the... Read More
Columbus close its third Investment Biotech Fund with 120€M

 Read complete article here Read More
Vivet Therapeutics announces agreement with Mirum Pharmaceuticals

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial... Read More
Aura Biosciences Announces Oversubscribed $80 Million Financing

CAMBRIDGE, March 2021 -- Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for... Read More